Firdapse Generic

Automatically clustered newsroom coverage around one of the most active themes in the intellectual property ecosystem.

LitigationUSA

Deal reached in US legal dispute over Firdapse generic for LEMS

Catalyst Pharmaceuticals and Lupin have settled a legal dispute related to Lupin’s generic version of Firdapse (amifampridine) — an approved brand-name treatment for Lambert-Eaton myasthenic syndrome (LEMS).

Wednesday, April 29, 2026

Newsletters & Digests

Follow Firdapse Generic

Subscribe to receive daily and weekly newsroom coverage aligned to this trend cluster and adjacent IP developments.

Explore

All newsroom coverage Filtered archive